PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
22.84%
Net income growth above 1.5x TRAW's 15.11%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
7.12%
Some D&A expansion while TRAW is negative at -12.50%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-26.57%
Both cut yoy SBC, with TRAW at -6.47%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-21.66%
Negative yoy working capital usage while TRAW is 535.35%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both negative yoy AP, with TRAW at -146.23%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
161.21%
Growth well above TRAW's 286.10%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
200.00%
Some yoy increase while TRAW is negative at -48.52%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
22.87%
Operating cash flow growth 1.25-1.5x TRAW's 16.06%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
-183.51%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-183.51%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-107.12%
Negative yoy issuance while TRAW is 201.93%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.